Suppr超能文献

肥胖、脂肪肝疾病与肠道微生物群

Obesity, fatty liver disease and intestinal microbiota.

作者信息

Arslan Nur

机构信息

Nur Arslan, Department of Pediatrics, Division of Pediatric Gastroenterology, Nutrition and Metabolism, Dokuz Eylul University Faculty of Medicine, Izmir 35340, Turkey.

出版信息

World J Gastroenterol. 2014 Nov 28;20(44):16452-63. doi: 10.3748/wjg.v20.i44.16452.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disorder that is increasing in prevalence with the worldwide epidemic of obesity. NAFLD is the hepatic manifestation of the metabolic syndrome. The term NAFLD describes a spectrum of liver pathology ranges from simple steatosis to steatosis with inflammation nonalcoholic steatohepatitis and even cirrhosis. Metabolic syndrome and NAFLD also predict hepatocellular carcinoma. Many genetic and environmental factors have been suggested to contribute to the development of obesity and NAFLD, but the exact mechanisms are not known. Intestinal ecosystem contains trillions of microorganisms including bacteria, Archaea, yeasts and viruses. Several studies support the relationship between the intestinal microbial changes and obesity and also its complications, including insulin resistance and NAFLD. Given that the gut and liver are connected by the portal venous system, it makes the liver more vulnerable to translocation of bacteria, bacterial products, endotoxins or secreted cytokines. Altered intestinal microbiota (dysbiosis) may stimulate hepatic fat deposition through several mechanisms: regulation of gut permeability, increasing low-grade inflammation, modulation of dietary choline metabolism, regulation of bile acid metabolism and producing endogenous ethanol. Regulation of intestinal microbial ecosystem by diet modifications or by using probiotics and prebiotics as a treatment for obesity and its complications might be the issue of further investigations.

摘要

非酒精性脂肪性肝病(NAFLD)是一种慢性肝脏疾病,随着全球肥胖症的流行,其患病率正在上升。NAFLD是代谢综合征的肝脏表现。术语NAFLD描述了一系列肝脏病理变化,从单纯性脂肪变性到伴有炎症的脂肪变性(非酒精性脂肪性肝炎),甚至肝硬化。代谢综合征和NAFLD也预示着肝细胞癌。许多遗传和环境因素被认为与肥胖症和NAFLD的发生有关,但确切机制尚不清楚。肠道生态系统包含数万亿微生物,包括细菌、古菌、酵母和病毒。几项研究支持肠道微生物变化与肥胖症及其并发症(包括胰岛素抵抗和NAFLD)之间的关系。鉴于肠道和肝脏通过门静脉系统相连,这使得肝脏更容易受到细菌、细菌产物、内毒素或分泌的细胞因子易位的影响。肠道微生物群改变(生态失调)可能通过多种机制刺激肝脏脂肪沉积:调节肠道通透性、增加低度炎症、调节膳食胆碱代谢、调节胆汁酸代谢以及产生内源性乙醇。通过饮食调整或使用益生菌和益生元来调节肠道微生物生态系统,以此作为肥胖症及其并发症的治疗方法,可能是进一步研究的课题。

相似文献

1
Obesity, fatty liver disease and intestinal microbiota.肥胖、脂肪肝疾病与肠道微生物群
World J Gastroenterol. 2014 Nov 28;20(44):16452-63. doi: 10.3748/wjg.v20.i44.16452.
5
Gut microbiota and host metabolism in liver cirrhosis.肝硬化中的肠道微生物群与宿主代谢
World J Gastroenterol. 2015 Nov 7;21(41):11597-608. doi: 10.3748/wjg.v21.i41.11597.
6
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群:非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
7
Obesity and NAFLD: the role of bacteria and microbiota.肥胖与非酒精性脂肪性肝病:细菌和微生物组的作用。
Clin Liver Dis. 2014 Feb;18(1):59-71. doi: 10.1016/j.cld.2013.09.002. Epub 2013 Oct 24.
9
Gut microbiota and non-alcoholic fatty liver disease.肠道微生物群与非酒精性脂肪性肝病
Hepatobiliary Pancreat Dis Int. 2015 Dec;14(6):572-81. doi: 10.1016/s1499-3872(15)60026-1.

引用本文的文献

本文引用的文献

1
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Biomed Res Int. 2014;2014:106247. doi: 10.1155/2014/106247. Epub 2014 Mar 11.
4
Clinical consequences of diet-induced dysbiosis.饮食诱导的菌群失调的临床后果。
Ann Nutr Metab. 2013;63 Suppl 2:28-40. doi: 10.1159/000354902. Epub 2013 Nov 8.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验